NAS10029,447+1.73%S&P7,638+1.14%GOLD$4,412+0.27%BTC$77,965+2.04%VIX15.48+0.26%live tape · as of 17:00 UTC
The Screen · Healthcare · Biotechnology
Jazz Pharmaceuticals plc
JAZZ · NASDAQ · USD · Market cap $15.9B · 2,890 employees
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
FAIL · Does not pass the screen
245.57 USD
At the last full screen 2026-09-02
Screened 2026-09-02 · the tape above runs as of 17:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Jazz Pharmaceuticals plc holds its Distribution at $245.57. The statistical read favours the buyers, held for 18 days.
As held on the ledger · 2026-09-02
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 18 days
Price at the screen
$245.57
Valuation
16.81 trailing · 9.53 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.36
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
46.52%
Below 33%
Interest-bearing debt is 46.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
9.01%
Below 33%
Cash held in interest-bearing accounts and securities is 9.0% of assets, under the one-third limit.
Pass
Receivables
19.06%
Below 49%
Money owed to the company is 19.1% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-02 screen. The gold marker is the market price at the same screen. A 31.1% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus Buy. The average target sits +22% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Jazz sells sleep drugs yet barely turns a profit
Picture a patient finally getting rest thanks to a specialist drug, only to learn the company behind it scrapes by on wafer-thin returns. Jazz grows revenue at 19 percent a year and clears the ethical screen, yet posts a 1 percent profit margin and 1 percent ROE with nothing more than a narrow moat. Analysts like the shares at a 9.6 times forward multiple, but our opportunity rating stays at none.
The low multiples look tempting next to steady top-line growth. Still, single-digit returns on equity in a research-heavy field usually signal either heavy spending that fails to scale or pricing pressure that caps real earnings power. We see no margin of safety worth chasing here.
Currency moves, patent cliffs and regulatory shifts in Europe add the usual sector risks, yet the core problem remains the inability to convert sales into meaningful profits. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
JAZZ trades on NASDAQ (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 41% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 102%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $257.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 41% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 102%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $257.
2026-07-18Markup$230.56+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 41% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 102%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (19 analysts) rates it buy, with a mean price target of $257.
2026-07-03Markup$230.56+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$230.56Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
